Plaque regression - A new target for antiatherosclerotic therapy

American Heart Journal

Volumn 149, Issue 3, 2005, Pages 384-387

  Karha, Juhana ^a   Bhatt, Deepak L ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN;

ANTIINFLAMMATORY ACTIVITY; ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HUMAN; INTERMETHOD COMPARISON; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK REDUCTION;

EID: 17844387593     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.11.003     Document Type: Editorial

References (37)

1. B. Pitt, G.B. Mancini, and S.G. Ellis Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation J. Am. Coll. Cardiol. 26 1995 1133 1139
2. J.W. Jukema, A.V. Bruschke, and A.J. van Boven Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS) Circulation 91 1995 2528 2540
3. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS) Lancet 344 1994 633 638
4. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators N. Engl. J. Med. 336 1997 153 162
5. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N. Engl. J. Med. 345 2001 1583 1592
6. A.J. Taylor, S.M. Kent, and P.J. Flaherty ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness Circulation 106 2002 2055 2060
7. T.J. Smilde, S. van Wissen, and H. Wollersheim Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial Lancet 357 2001 577 581
8. S.E. Nissen, E.M. Tuzcu, and P. Schoenhagen Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 291 2004 1071 1080
9. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
10. C.P. Cannon, E. Braunwald, and C.H. McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 2004 1495 1504
11. E.J. Topol Intensive statin therapy-a sea change in cardiovascular prevention N. Engl. J. Med. 350 2004 1562 1564
12. A.S. Petronio, G. Amoroso, and U. Limbruno Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomised study with intravascular ultrasound Am. Heart. J. 149 2005 520 526
13. L.O. Jensen, P. Thayssen, and K.E. Pedersen Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study Circulation 110 2004 265 270
14. S. Okazaki, T. Yokoyama, and K. Miyauchi Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study Circulation 110 2004 1061 1068
15. G.G. Schwartz, A.G. Olsson, and M.D. Ezekowitz Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial JAMA 285 2001 1711 1718
16. J.A. de Lemos, M.A. Blazing, and S.D. Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
17. S.E. Nissen High-dose statins in acute coronary syndromes: not just lipid levels JAMA 292 2004 1365 1367
18. R. Mills, and D.L. Bhatt The Yin and Yang of arterial inflammation J. Am. Coll. Cardiol. 44 2004 50 52
19. M.H. Shishehbor, and D.L. Bhatt Inflammation and atherosclerosis Curr. Atheroscler. Rep. 6 2004 131 139
20. M.H. Shishehbor, D.L. Bhatt, and E.J. Topol Using C-reactive protein to assess cardiovascular disease risk Cleve. Clin. J. Med. 70 2003 634 640
21. D.L. Bhatt, and E.J. Topol Need to test the arterial inflammation hypothesis Circulation 106 2002 136 140
22. D.L. Bhatt Inflammation and restenosis: is there a link? Am. Heart J. 147 2004 945 947
23. A.W. Chan, D.L. Bhatt, and D.P. Chew Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention Circulation 105 2002 691 696
24. A.W. Chan, D.L. Bhatt, and D.P. Chew Relation of inflammation and benefit of statins after percutaneous coronary interventions Circulation 107 2003 1750 1756
25. V. Pasceri, G. Patti, and A. Nusca Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study Circulation 110 2004 674 678
26. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
27. M.E. Brousseau, E.J. Schaefer, and M.L. Wolfe Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol N. Engl. J. Med. 350 2004 1505 1515
28. A.J. Taylor ARBITER-2 Trial Presented at AHA 2004
29. J.C. Tardif, J. Gregoire, and L. Schwartz Effects of AGI-1067 and probucol after percutaneous coronary interventions Circulation 107 2003 552 558
30. J.S. Sidhu, Z. Kaposzta, and H.S. Markus Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus Arterioscler. Thromb. Vasc. Biol. 24 2004 930 934
31. S. Massberg, K. Brand, and S. Gruner A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation J. Exp. Med. 196 2002 887 896
32. Y. Huo, A. Schober, and S.B. Forlow Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E Nat. Med. 9 2003 61 67
33. M. MacMahon, C. Kirkpatrick, and C.E. Cummings A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Nutr. Metab. Cardiovasc. Dis. 10 2000 195 203
34. J. Genest, and T.R. Pedersen Prevention of cardiovascular ischemic events: high-risk and secondary prevention Circulation 107 2003 2059 2065
35. D.D. Waters, J.R. Guyton, and D.M. Herrington Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 93 2004 154 158
36. P.M. Ridker Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial Circulation 108 2003 2292 2297
37. J.A. Lima, M.Y. Desai, and H. Steen Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy Circulation 110 2004 2336 2341